FDA Gives Approval To Baxalta Drug Adynovate For Patients With Hemophilia A

FDA gave approval to Baxalta drug Adynovate for the treatment of patients with Hemophilia A. The drug is said to stay longer in the blood, thus reducing the need for frequent injections.